Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection

Helicobacter Infection Clinical Trial

— 960025  

Official title:

Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00656968
• Other study ID #: KMU-IRB00003151
• Secondary ID: VGHKS95-CT3-11
• Status: Completed
• Phase: Phase 4
• First received: January 3, 2008
• Last updated: September 14, 2015
• Start date: May 2007
• Est. completion date: June 2010

Study information

• Verified date: September 2015
• Source: Kaohsiung Veterans General Hospital.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Helicobacter pylori is a bacteria that infects the lining of the stomach and is associated with ulcers. Helicobacter pylori may also increase the long-term risk of developing certain forms of gastric cancer. Curing this infection generally requires that patients take 2 or more antibiotic medications and a stomach acid suppressing medication for about two weeks. Current treatments do not always cure the infection and a new treatment is being tested in this study. The drugs involved in the new 4 drug treatment have been widely used for treatment of this infection. It remains unknown what is the best and most cost effective way to give them. This study will compare three different ways of using these drugs.

Subjects must have active Helicobacter pylori infection in order to participate in this study.

Description:

The purpose of this study is to compare different methods of giving combination drug therapy for treating Helicobacter pylori infection of the stomach. The entire study will last less than 2 years. Each subject will be participating in the study for approximately 60 days.

A total of 360 subjects will be asked to participate in this study.

Before participating in this study, subject's must have undergone to confirm the presence and to assess the susceptibility of Helicobacter pylori. Qualified subjects will receive 4 drugs which are to be taken as part of the study treatment: an acid suppressing drug (name), amoxicillin, clarithromycin and metronidazole. The doses are 1 grams of amoxicillin, 40 mg of esomeprazole (Nexium), 500 mg of metronidazole and 250 mg of clarithromycin. Each drug will be given twice a day to be taken twice a day with the morning and evening meals. Subjects will receive one of three different combinations. The choice of which will be randomly chosen by the use of a computer program. The regimes are: all 4 drugs daily for 5 days, all 4 drugs daily for 10 days, and two drugs (esomeprazole and amoxicillin) for 5 days then all for drugs for 5 additional days.

Subjects will be asked to return within 4 days after completion of the treatment to evaluate how they did with the drugs. They will be asked bring back all unused medication and the bottles or containers that the medicine was packaged in. Your medication use and tolerance to the study drugs will be assessed. The treatment portion of the study will be complete at this point.

Evaluation of the effect of the treatment will take place 4-6 weeks after the end of therapy. Subjects will come back to the study site and will have a UBT or repeat endoscopy, if clinically indicated to verify that the Helicobacter pylori has been cured. Subjects will be asked not to take antibiotics or any other drugs that may affect the outcome of the breath test used to confirm that the treatment was successful.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 232
• Est. completion date: June 2010
• Est. primary completion date: June 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male or non-pregnant female aged 18 to 75 years inclusively.

• Mental and legal ability to give a written informed consent.

• Active H. pylori infection.

Exclusion Criteria:

• Previous surgery of the stomach such as partial gastrectomy.

• Use of antibiotics within the preceding 30 days.

• Regular use of bismuth compounds (>3 times per week) in the 30 days before enrollment.

• Presence of serious medical condition(s) precluding participation or endoscopy with biopsy.

• Use of concomitant medication(s) known to interact with study medication.

• Presence of Zollinger-Ellison Syndrome.

• Pregnancy or lactation.

• Allergy to any of the study medications.

• Contraindication(s) to the use of any of the study drugs.

• Participation in a clinical trial within the last 30 days.

• Unwillingness to abstain from alcoholic beverages.

• Patients taking other medications including warfarin, antipsychotics, or chronic NSAIDs will also be excluded. Aspirin at a dose not more than 325 mg/day will be permitted.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Helicobacter Infection
• Helicobacter Infections
• Infection

Intervention

Drug:
• 10-day sequential treatment
esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
• 10-day concomitant therapy
esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10

Locations

Country	Name	City	State
Taiwan	Chung-Ho Hospital	Kaohsiung
Taiwan	Kaohsiung Veterans General Hospital	Kaohsiung

Sponsors (2)

Lead Sponsor	Collaborator
Kaohsiung Veterans General Hospital.	Baylor College of Medicine

Country where clinical trial is conducted

Taiwan, 

References & Publications (1)

Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Boscarelli G, Piscitelli D, Amoruso A, Di Leo A, Miniello VL, Francavilla A, Cavallo L, Ierardi E. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology. 2005 Nov;129(5):1414-9. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants in Which H. Pylori Was Eradicated	Evaluate eradication outcome by endoscopy urease test and histology or urea breath test	one month after finishing study drugs	No
Primary	Number of Participants Who Had Good Drug Compliance	Good drug compliance is defined as taking equal to or more than 80% of eradication medicines	one month after finishing test therapy	No

External Links

•   CRIER Database
•   Graham, D.Y. / Opekun, A.R.